ClinicalTrials.gg
RecruitingNCT04726241Updated Nov 19, 2026

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

A Phase 1/2 interventional study of Biospecimen Collection in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Acute Myeloid Leukemia Post Cytotoxic Therapy, sponsored by PedAL BCU, LLC. Recruiting at 185 sites in 5 countries. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by PedAL BCU, LLC · Phase 1/2, Interventional, and Screening

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 19, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
960
Allocation
Not applicable
Ages
Up to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
12th of 1,269
960 · median 35
Started
2022
with 49 others
Phase 1/2
153 of 1,545
17 open now
Primary completion
2032-12
later than 262 of 272 live
Registered
1,315th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 12th largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 50 that started in 2022, is one of 153 in phase 1/2, reaches primary completion later than 262 of the 272 other live ones, and was the 1,315th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Read the detailed description

PRIMARY OBJECTIVES:

I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials.

II. To maintain a longitudinal and comprehensive registry, as well as a specimen bank, from relapse in children and young adults with acute leukemias.

OUTLINE:

Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).

After completion of study, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Juvenile Myelomonocytic Leukemia
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome Post Cytotoxic Therapy
  • Myeloid Leukemia Associated With Down Syndrome
04

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must be less than 22 years of age at the time of study enrollment
  • Patient must have one of the following at the time of study enrollment:

    • Patient has known or suspected (including primary refractory) AML as defined in protocol

      • This includes isolated myeloid sarcoma
    • Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS)
    • Patient has known or suspected relapsed ALL as defined in protocol that meets one of the following criteria:

      • Second or greater B-ALL medullary relapse, excluding KMT2Ar
      • Any first or greater B-ALL medullary relapse involving KMT2Ar
      • Any first or greater T-ALL medullary relapse with or without KMT2Ar
    • Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia (MPAL) as defined in protocol
    • Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment-related AML (t-AML)
    • Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS) or treatment-related myelodysplastic syndrome (t-MDS)

      • Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse.
    • Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML)

      • Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse.
  • All patients and/or their parents or legal guardians must sign a written
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Screening (biospecimen collection)

    Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).

    Procedure: Biospecimen Collection

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood and/or bone marrow samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

06

What researchers measure

Primary outcomes

  1. Proportion of patients with identification of a priori specified genomic and immunophenotypic targets who enroll on a sub-trial

    The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confidence interval will be constructed.

    Time frame: Up to 5 years

  2. Maintain a longitudinal and comprehensive registry, as well as specimen bank of children and young adults with acute leukemias

    The number of patients with at least one specimen submitted to the bank will be reported.

    Time frame: Up to 5 years

07

Study locations

174 of 185 sites recruiting

Showing the first 100 of 185 sites across 5 countries. Choose a country and city above to see the rest.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2032, 128 months after the start.

Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's planned 128 months is above that.

Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2030 → Dec 2032 and completion Dec 2030 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2021
First posted
Jan 27, 2021
StartActual
Apr 18, 2022
Primary completionEst.
Dec 31, 2032was Dec 2030
CompletionEst.
Dec 31, 2032was Dec 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (2 now suspended, 1 now recruiting)
Show 3 sites
  • UCSF Medical Center-Mission Bay · San Francisco, United StatesRecruiting→Suspended
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, United StatesSuspended→Recruiting
  • West Virginia University Healthcare · Morgantown, United StatesRecruiting→Suspended
Show site
  • Newark Beth Israel Medical Center · Newark, United States
Nov 19, 2026
Primary completion
Dec 31, 2030→Dec 31, 2032
Nov 17, 2026
Study completion
Dec 31, 2030→Dec 31, 2032
Nov 17, 2026
Site contacts
Changed at 11 sites. See the sites
Show 11 sites
  • UCSF Medical Center-Mission Bay · San Francisco, United StatesContact removed c•••@ucsf.edu · •••3222Contact removed (no phone or email listed)
  • Nicklaus Children's Hospital · Miami, United StatesContact person changed (no phone or email listed)
  • Memorial Health University Medical Center · Savannah, United StatesContact person changed (no phone or email listed)
  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation · Las Vegas, United StatesContact person changed (no phone or email listed)
  • Summerlin Hospital Medical Center · Las Vegas, United StatesContact person changed (no phone or email listed)
  • Renown Regional Medical Center · Reno, United StatesContact person changed (no phone or email listed)
  • Saint Peter's University Hospital · New Brunswick, United StatesContact k•••@saintpetersuh.com→o•••@saintpetersuh.com
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, United StatesContact added C•••@nyulangone.orgContact added (no phone or email listed)
  • Children's Hospital Medical Center of Akron · Akron, United StatesContact added (no phone or email listed)
  • West Virginia University Healthcare · Morgantown, United StatesContact removed c•••@hsc.wvu.edu · •••7374Contact removed (no phone or email listed)
  • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont · Sherbrooke, CanadaContact person changed (no phone or email listed)
Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    1 site added. 3 sites changed recruiting status (2 now suspended, 1 now recruiting)
    Show 3 sites
    • UCSF Medical Center-Mission Bay · San Francisco, United StatesRecruiting→Suspended
    • Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, United StatesSuspended→Recruiting
    • West Virginia University Healthcare · Morgantown, United StatesRecruiting→Suspended
    Show site
    • Newark Beth Israel Medical Center · Newark, United States
    Site contacts Changed at 11 sites. See the sites
    Show 11 sites
    • UCSF Medical Center-Mission Bay · San Francisco, United StatesContact removed c•••@ucsf.edu · •••3222Contact removed (no phone or email listed)
    • Nicklaus Children's Hospital · Miami, United StatesContact person changed (no phone or email listed)
    • Memorial Health University Medical Center · Savannah, United StatesContact person changed (no phone or email listed)
    • Alliance for Childhood Diseases/Cure 4 the Kids Foundation · Las Vegas, United StatesContact person changed (no phone or email listed)
    • Summerlin Hospital Medical Center · Las Vegas, United StatesContact person changed (no phone or email listed)
    • Renown Regional Medical Center · Reno, United StatesContact person changed (no phone or email listed)
    • Saint Peter's University Hospital · New Brunswick, United StatesContact k•••@saintpetersuh.com→o•••@saintpetersuh.com
    • Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, United StatesContact added C•••@nyulangone.orgContact added (no phone or email listed)
    • Children's Hospital Medical Center of Akron · Akron, United StatesContact added (no phone or email listed)
    • West Virginia University Healthcare · Morgantown, United StatesContact removed c•••@hsc.wvu.edu · •••7374Contact removed (no phone or email listed)
    • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont · Sherbrooke, CanadaContact person changed (no phone or email listed)
    + 1 other change: verification date
  2. Nov 17, 2026
    Primary completion Dec 31, 2030→Dec 31, 2032
    Study completion Dec 31, 2030→Dec 31, 2032
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04726241
Lead sponsor
PedAL BCU, LLC
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Apr 18, 2022
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 19, 2026

Study contacts

Michele S Redell
principal investigator · Children's Oncology Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion